Kevin Brennan - 01 May 2024 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
SVP, FINANCE AND ACCOUNTING
Signature
/s/ Julia Walcott, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
01 May 2024
Transactions value $
$0
Form type
4
Date filed
03 May 2024, 16:10
Previous filing
03 Jan 2024
Next filing
02 Oct 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +20K $0.00 20K 01 May 2024 Common Stock 20K $1.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was granted on May 1, 2024 and shall vest on June 1, 2024 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until May 1, 2028.